Defining SARS-CoV-2 breakthrough infection needing hospitalization in mass vaccination era: from disease-centered to patient-centered care

Andrea Ticinesi\textsuperscript{1,2}, Antonio Nouvenne\textsuperscript{2}, Alberto Parise\textsuperscript{2}, Beatrice Prati\textsuperscript{2}, Tiziana Meschi\textsuperscript{1,2}

\textsuperscript{1}University of Parma, Department of Medicine and Surgery, Via Antonio Gramsci 14, 43126 Parma, Italy; \textsuperscript{2}Azienda Ospedaliero-Universitaria di Parma, Geriatric-Rehabilitation Department, Via Antonio Gramsci 14, 43126 Parma, Italy

Abstract. After the implementation of mass vaccination campaigns, breakthrough infections by SARS-CoV-2 are being increasingly observed worldwide, due to high pervasiveness of viral spread, emergence of novel variants, progressive ease of restrictive measures and waning protection against infection. Although breakthrough infections have generally lower clinical severity than COVID-19 in unvaccinated subjects, a consistent number of patients may still require hospitalization. These patients are generally old, frail and with a high number of comorbidities. Despite COVID-19-related symptoms are generally milder, they may still exhibit complicated clinical course for their intrinsic clinical complexity. The abrupt emergence of the SARS-CoV-2 omicron variant in the final weeks of 2021 could also contribute to increase the burden of breakthrough infection needing hospitalization, due to its extremely high infectiousness and the serious concerns over failure of immune response induced by available vaccines. The organization of hospital care should thus consider the changing epidemiology of patients admitted with SARS-CoV-2 infection in the post-vaccine era, to improve the quality and appropriateness of care and specifically address the needs of each patient.

Keywords: interstitial pneumonia, organization of care, COVID-19 vaccine, breakthrough COVID-19 infection

Introduction

The epidemiological context

In the second half of 2021, the trend of the COVID-19 pandemic across different countries can be viewed as the result of a complex and fragile equilibrium between, on one side, the diffusion of highly-transmissible SARS-CoV-2 variants, seasonal trends in the spread of coronaviruses and relaxation of restrictive measures, and, on the other side, mass vaccination campaigns (1). Current vaccines exhibit high effectiveness against SARS-CoV-2 transmission and development of severe forms of COVID-19 (2), that seems to be only mildly affected by the worldwide spread of the delta variant (3). However, the extremely high pervasiveness of viral spread across the world, the reprise of international travels and the progressive ease of universal masking and social distancing make the occurrence of SARS-CoV-2 infection frequent also in those who have completed vaccine schedules (4,5).

Furthermore, concerns over waning immunity have also been recently raised, basing on real-world data of subjects vaccinated at the beginning of the campaign (6,7). This phenomenon may be emphasized in older and frail subjects, due to immunosenescence and immune depression, and represents the rationale for the recent recommendation of a "booster" vaccine dose (6,7). In fact, anti-SARS-CoV-2 vaccine registration trials were not focused on older frail populations, and were not designed to measure the extent and duration of protective response in these subjects (8).
SARS-CoV-2 breakthrough infections in hospital

The epidemiological context after the implementation of mass vaccination campaigns has deep implications for hospital care of COVID-19 patients. From summer 2021 onwards, the number of patients with SARS-CoV-2 breakthrough infection needing hospital admission has been increasing (4,5). This phenomenon should not be attributed uniquely to vaccine failure, spread of novel SARS-CoV-2 variants and waning immunity, but is also the result of the massive viral spread and infective capacity.

Patients with breakthrough infections generally have milder clinical courses and different care needs than their unvaccinated counterparts, who display the typical clinical presentation of severe COVID-19, with rapidly progressive respiratory failure due to interstitial pneumonia (9,10). Epidemiological data suggest that vaccines are able to modify the natural history of SARS-CoV-2 infection, implying lower risks of Intensive Care Unit (ICU) admission and mortality (9-10). However, few studies have defined the clinical characteristics and care needs of patients hospitalized with SARS-CoV-2 breakthrough infection to date.

A large multicenter study from the United States has recently highlighted that vaccinated patients needing hospital admission for COVID-19 were older and with a higher number of comorbidities than unvaccinated patients (10). Furthermore, the highest level of respiratory illness during hospital stay was significantly lower in vaccinated patients, who also experienced shorter duration of stay and higher frequency of recovery (10). These results match those previously obtained by Juthani et al. (5), who showed that 46% of patients who needed hospital admission for SARS-CoV-2 breakthrough infection had no respiratory symptoms, and the positive Polymerase-Chain Reaction (PCR) test for SARS-CoV-2 was an incidental finding. Juthani et al. also detected a significant burden of comorbidities, including overweight, cardiovascular disease, cancer and diabetes, in those patients admitted with SARS-CoV-2 breakthrough infection (5).

Overall, these findings suggest that the clinical characteristics of patients needing hospitalization for COVID-19 have been substantially modified by mass vaccination campaigns. Before these campaigns, almost all patients hospitalized with COVID-19 had severe respiratory failure, irrespective of the presence of comorbidities (11). This clinical picture is still dominant in unvaccinated patients who are currently admitted to hospital. However, a substantial part of COVID-19-related admissions nowadays involves subjects with breakthrough infection, who generally have milder respiratory involvement and complex clinical pictures due to the presence of multiple comorbidities. Significant respiratory involvement may anyway be present also in those patients who have completed the original two-dose vaccinal schedule more than three months before infection with SARS-CoV-2, and have not received the booster dose yet (12).

A classification of breakthrough infections in hospital

In Table 1, we propose a real-world classification of patients needing hospitalization for COVID-19 in the post-vaccination era. Each category of patients may correspond to a different pathway of care, involving wards with different care intensity and specialist know-how. Community facilities or hospital-at-home programs consisting in multidisciplinary mobile units may be even involved for milder cases (13).

In fact, in the post-vaccine era, hospitalization in patients with SARS-CoV-2 breakthrough infection may occur for clinical reasons unrelated to COVID-19, and the finding of positive molecular testing on admission may even be unexpected. In other cases, generally regarding older patients with multimorbidity and frailty who received vaccination in the early phases of the campaign, COVID-19 may represent just one of multiple clinical conditions, and sometimes has even a lower clinical priority than another index disease. In these patients the occurrence of respiratory failure, if present, cannot be uniquely attributed to COVID-19, but can also be related to pre-existing cardiorespiratory conditions. Some of these patients may also have experienced previous SARS-CoV-2 infections, so that
Table 1. Characteristics of patients hospitalized with positive COVID-19 molecular tests in the mass vaccination era and proposal of their best setting of care.

| Type of patient                        | Characteristics                                                                 | Best setting of care                                                                 |
|----------------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Unvaccinated                           | Fever, respiratory failure, chest imaging evidence of interstitial pneumonia      | Pneumology<br>Infecitvology<br>Internal medicine<br>ICU or subintensive care         |
| Breakthrough infection, asymptomatic   | Admitted for reasons unrelated to COVID-19, unexpected positivity on RT-PCR testing for SARS-CoV-2 | Internal medicine<br>Other specialty according to the index clinical picture          |
| Breakthrough infection, paucisymptomatic| Complex clinical presentation exhibiting some features (fever, dyspnea) compatible with both COVID-19 and other pre-existing diseases, chest imaging negative or undetermined for interstitial pneumonia, presence of multimorbidity and/or frailty. COVID-19 is not the index disease but simply one condition with the same or lower priority than other conditions | Internal medicine<br>Geriatrics<br>Community facilities (milder cases)<br>Hospital-at-home programs (milder cases) |
| Breakthrough infection, symptomatic    | Fever, respiratory failure, chest imaging evidence of interstitial pneumonia, usually with reduced severity and potential of evolution towards severe forms. Comorbidities may be present, but COVID-19 holds the highest priority in care. | Pneumology<br>Infecitvology<br>Internal medicine or geriatrics<br>ICU or subintensive care |
| Long-term positivity (vaccinated or not)| Documented previous episode of COVID-19, admitted for reasons unrelated to COVID-19 or for complex cardiorespiratory symptoms not certainly related to acute interstitial pneumonia, possible long-COVID features, persistent viral shedding from upper airway mucosa | Internal medicine<br>Geriatrics<br>Community facilities (milder cases)<br>Hospital-at-home programs (milder cases) |

It is difficult to determine whether the occurrence of a novel positive molecular test represents reinfection or long-term positivity due to persistent viral shedding.

Some patients needing hospitalization for SARS-CoV-2 breakthrough infection may also present with the typical COVID-19 picture: fever, progressive respiratory failure, chest imaging compatible with interstitial pneumonia. These patients generally have received their last dose of anti-COVID-19 vaccine a longer time before other patients with breakthrough infection (generally more than three months), or have a substantial burden of frailty and multimorbidity, representing significant risk factors for both severe outcomes of COVID-19 and vaccine failure. Furthermore, the occurrence of such cases could be more frequent during winter and early spring, when the seasonal spread of SARS-CoV-2 is generally higher and associated with more severe clinical pictures (11). The care needs of these patients are similar to unvaccinated counterparts, although the prognosis is more favorable in terms of risk of ICU admission and mortality. A high degree of inter-individual variability in the clinical course and prognosis of the disease is however present, so that unfavorable outcomes cannot unfortunately be ruled out also in patients who completed their vaccinal schedule.

Medical history, with particular focus on vaccine timing, and chest imaging, particularly involving computed tomography or ultrasound (14), could represent the main parameters for classifying patients with breakthrough infection upon admission.

Such classification could be useful not only for epidemiological and research purposes, but also for organizing hospital care. In fact, unvaccinated patients and patients with symptomatic breakthrough infection may be best managed in specialist wards dedicated to COVID-19 with priority access to ICU and subintensive care. Conversely, patients belonging to the “asymptomatic”, “paucisymptomatic” and “persistent positivity” groups may be best managed in internal medicine and geriatrics COVID-19 wards, where clinicians have the know-how for managing complex pictures characterized by frailty and multimorbidity (15-17).

The organization of hospital care, which has been disrupted by the sudden emergence of COVID-19...
pandemic in 2020, should in fact be adapted to the changing epidemiology and needs of patients admitted with positive PCR tests for SARS-CoV-2 (18). Before the pandemic, organization of medical wards by care intensity has prompted significant advantages in terms of appropriateness, quality and safety of care, particularly for older patients with multiple chronic conditions and frailty (19,20). The changes in COVID-19 epidemiology driven by mass vaccination campaigns should thus induce a paradigm change also in hospital organization, from a disease-centered model, to a patient-centered model considering that nowadays patients needing hospital admission for COVID-19 do not always have the same clinical picture and thus have different care needs.

The omicron threat

The abrupt emergence of the SARS-CoV-2 omicron variant in the last weeks of 2021 represents a serious threat for public health and functioning of healthcare systems (21-22). The omicron variant, first described in South Africa in November 2021, is characterized by an unprecedented infectiousness, with doubling times of cases esteemed in less than three days (21-22). Furthermore, molecular investigations suggest that the protection conferred by the current vaccines against SARS-CoV-2 is significantly lower for this variant than for other variants that have caused outbreaks earlier in 2021 (23).

Preliminary data from clinical investigations suggest that the omicron variant is associated with milder disease and substantially reduced risk of hospital admission than the delta variant (24-27). However, from a public health perspective, it is unclear whether this advantage balances the extremely high infectiousness and rapidity of spread among the population. In fact, there are substantial concerns that the omicron variant can cause an extremely high number of hospital admissions, even involving vaccinated patients. This circumstance could lead to hospital overcrowding and substantial difficulties in delivering care for clinical conditions unrelated to COVID-19 (28).

In this scenario, hospitalization of patients with SARS-CoV-2 breakthrough infection is more and more probable in the near future. Unfortunately, solid data on the clinical pictures caused by the omicron variant in patients needing hospital admission are lacking at the time of writing. However, prompt recognition of the severity of respiratory involvement and its clinical priority with respect of other coexisting conditions remains of utmost importance for delivering the best care in the most appropriate clinical setting. The high diffusion of omicron infections makes it also fundamental to avoid hospitalization whenever possible. Hospital-at-home services specifically dedicated to COVID-19 patients could be thus implemented to relieve the overcrowding of acute-care wards (13, 29).

Conclusions

Mass vaccination campaigns and the emergence of novel viral variants have substantially modified the epidemiology of COVID-19 also from a hospital perspective. Despite the increasing frequency of SARS-CoV-2 breakthrough infections, to date few studies have focused on the clinical characteristics and care needs of patients who need hospital admission for SARS-CoV-2 infection after completion of the vaccination schedule, and none of them concerned the omicron variant. A consistent fraction of these patients have only mild or moderate respiratory involvement, but a high degree of clinical complexity due to older age, frailty and comorbidities. Hospital care should be organized in accordance with the needs of this novel category of COVID-19 patients, with tailored clinical pathways.

Conflict of Interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article. No specific funding must be reported for the present article.

Ethical Statement: This paper does not involve human research or personal data, so Ethics Committee Approval is not required.

References

1. Oliu-Barton M, Pradelski BSR, Algan Y, et al. Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines. Lancet Glob Health 2022;10(1):e142-e147.
2. Fiolet T, Kherabi Y, MacDonald CJ, et al. Comparing COVID-19 vaccines for their characteristics, efficacy and
Acta Biomed 2022; Vol. 93, N. 2: e2022182

5

effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect 2022;28(2):202-221.
3. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med 2021;385(7):585-594.
4. Agrawal U, Katikireddi SV, McCowen C, et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir Med 2021;9(12):1439-1449.
5. Juthani PV, Gupta A, Borges KA, et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis 2021;21(11):1485-1486.
6. Altman DM, Boyton RJ. Waning immunity to SARS-CoV-2: implications for vaccine booster strategies. Lancet Respir Med 2021;9(12):1356-1358.
7. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021;398(10316):2093-2100.
8. Soiza RL, Sicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing 2021;50(2):279-283.
9. Butt AA, Nafady-Hego H, Chemaitelly H, et al. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination. Int J Infect Dis 2021;110:353-358.
10. Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 2021;326(20):2043-2054.
11. Ticinesi A, Nouvenne A, Cerundolo N, et al. Trends of COVID-19 Admissions in an Italian Hub during the Pandemic Peak: Large Retrospective Study Focused on Older Subjects. J Clin Med 2021;10(5):1115.
12. Israel A, Merzon E, Schäffer AA, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ 2021;375:e66787.
13. Nouvenne A, Caminiti C, Diodati F, et al. Implementation of a strategy involving a multidisciplinary mobile unit team to prevent hospital admission in nursing home residents: protocol of a quasi-experimental study (MMU-1 study). BMJ Open 2020;10(2):e034742.
14. Nouvenne A, Zani MD, Milanesi G, et al. Lung ultrasound in COVID-19 pneumonia: correlations with chest CT on hospital admission. Respiration 2020;99(7):617-624.
15. Corazza GR, Formagnana P, Lenti MV. Bringing complexity into clinical practice: an internist’s approach. Eur J Intern Med 2019;61:9-14.
16. Lenti MV, Corazza GR, Di Sabatino A. Carving out a place for internal medicine during COVID-19 pandemic in Italy. J Intern Med 2020;288(2):263-265.
17. Corrao S, Natoli G, Nobili A, et al. Comorbidity does not mean clinical complexity: evidence from the RePoSI register. Intern Emerg Med 2020;15(4):621-628.
18. Meschi T, Rossi S, Volpi A, et al. Reorganization of a large academic hospital to face COVID-19 outbreak: The model of Parma, Emilia-Romagna region, Italy. Eur J Clin Invest 2020;50(6):e13250.
19. Meschi T, Ticinesi A, Prati B, et al. A novel organizational model to face the challenge of multimorbid elderly patients in an internal medicine setting: a case study from Parma Hospital, Italy. Intern Emerg Med 2016;11(5):667-676.
20. Liguori I, Russo G, Aran L, et al. Acute care hospital at different levels of intensity: the role of Geriatrician. Aging Clin Exp Res 2018;30(7):703-712.
21. Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature 2021;600(7887):21.
22. Abdool Karim SS, Abdool Karim Q. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 2021;398(10317):2126-2128.
23. Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect 2022;11(1):337-343.
24. Espenham L, Gunk T, Overvad M, et al. Epidemiological characterization of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. Euro Surveill 2021;26(50):2101146.
25. Brandal LG, MacDonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill 2021;26(50):2101147.
26. Abdulllah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in Africa, south Africa. Int J Infect Dis 2022;116:38-42.
27. Maslo C, Friedland R, Toubkin M, et al. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Wave. JAMA 2022;327(6):583-584.
28. Caminiti C, Maglietta G, Meschi T, et al. Effects of the COVID-19 Epidemic on Hospital Admissions for Non-Communicable Diseases in a Large Italian University-Hospital: A Descriptive Case-Series Study. J Clin Med 2021;10(4):880.
29. Nogués X, Sánchez-Martinez F, Castells X, et al. Hospital-at-Home Expands Hospital Capacity During COVID-19 Pandemic. J Am Med Dir Assoc 2021;22(5):939-942.

Correspondence
Received: 21 December 2021
Accepted: 5 January 2022
Dr. Andrea Ticinesi, M.D. Ph.D.
University of Parma, Department of Medicine and Surgery
Parma University-Hospital, Geriatric-Rehabilitation Department
Via Antonio Gramsci 14, 43126 Parma, Italy
E-mail: aticinesi@ao.pr.it; andrea.ticinesi@unipr.com
Phone: +39 0521 703871; Mobile: +39 3471845191;
Fax: +39 0521702383
ORCID-ID: 0000-0001-9171-8592